Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00160602 · ClinicalTrials.gov registry record · Phase 3
A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 590
- Enrollment target
NCT00160602: Completed Phase 3 study, sponsored by UCB Pharma.
NCT00160602 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 590 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00160602, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 590 participants
- Enrollment target
Study Summary
A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.
Interventions
- DRUG Certolizumab Pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 590 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00160602 record still lists
NCT00160602 is an interventional study that assigns participants to a tested intervention. The registered 590 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 1 intervention - of which Certolizumab Pegol is the first listed.
NCT00160602 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00160602 about?
NCT00160602 is a clinical study titled "A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis". A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.
What is the current status of trial NCT00160602?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 590 participants. The study started on 2005-06. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00160602?
The interventions under investigation include: Certolizumab Pegol (DRUG).
Who is sponsoring clinical trial NCT00160602?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00160602's enrollment target sits among peer trials
590 643rd of 2000 higher than 1,356 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01365169 · 590 participants · NA
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- NCT03774758 · 590 participants
Biomarkers for Risk Stratification in Lung Cancer
- NCT04747626 · 590 participants · NA
B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair
- NCT05722938 · 590 participants · Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia